Hansoh Pharma Enters $2 Billion+ Licensing Deal with Regeneron for GLP-1/GIP Dual Agonist HS-20094

On June 2, Hansoh Pharma announced that it had entered into a licensing agreement with Regeneron Pharmaceuticals, granting Regeneron the exclusive global license (excluding mainland China, Hong Kong, and Macao) to develop, manufacture, and commercialize HS-20094.

HS-20094 is an investigational GLP-1/GIP dual receptor agonist that has successfully completed multiple Phase 2 clinical trials with positive efficacy and safety data, and is currently undergoing Phase 3 clinical trials in China.

According to the agreement, Hansoh Pharma will obtain$80,000,000The down payment, and is eligible to receive payments based on the progress of the product’s development, regulatory approval, and commercialization.Up to $1.93 Billion in Milestone Payments, and a double-digit percentage royalty on potential future product sales.

References:
[1] Hansoh Pharma | Grants Regeneron Exclusive Overseas License for Investigational GLP-1/GIP Dual Receptor Agonist HS-20094. From https://mp.weixin.qq.com/s/rkaiYETNNE7XHS94837BpQ

Disclaimer: This article is for information exchange purposes only. The views expressed in the article do not represent the position of WuXi AppTec, nor does it mean that WuXi AppTec supports or opposes the views mentioned in the article. This article is not a recommendation for treatment plans. For guidance on treatment options, please visit a正规 hospital.